Recursion Pharmaceuticals reported mixed Q2 results, with revenue dropping to $7.67 million while net losses narrowed to $131.01 million. The company announced significant clinical milestones and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results